<unk>  (EB/TiB), sold under the brand names Femandren M and Folivirin, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone<unk>  (TiB), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is provided in the form of 1 mL ampoules containing 2.5 mg estradiol benzoate and 25 mg testosterone<unk>  in a microcrystalline aqueous suspension and is administered by intramuscular injection once every 4 to 6 weeks. EB/TiB reportedly has a duration of about 14 to 21 days. The medication is available only in the Czech Republic and Slovakia. EB/TiB was originally developed and marketed by the Swiss pharmaceutical company Ciba and was introduced for medical use by 1953, following the development of testosterone<unk>  in 1952. It was intermittently manufactured by Spofa and then Biotika and is now manufactured by BB Pharma. The effect of EB/TiB on gonadotropin levels in postmenopausal women have been studied. An oral tablet product with the same brand name of Femandren, containing ethinylestradiol and methyltestosterone, was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.
Estradiol benzoate/testosterone isobutyrate
Estradiol hexahydrobenzoate/hydroxyprogesterone caproate/testosterone hexahydrobenzoate
Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate
Estradiol benzoate butyrate
Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate
Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone caproate
Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate
Testosterone cyclohexylpropionate